Pharmacogenomics of gemcitabine: Can genetic studies lead to tailor-made therapy?

British Journal of Cancer

Volumn 97, Issue 2, 2007, Pages 145-151

  Ueno, H ^a   Kiyosawa, K ^b   Kaniwa, N ^c  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b ELI LILLY AND COMPANY   (United States)

^c NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Gemcitabine; Gene expression; Pharmacogenomics; Polymorphisms; Tailor made therapy

Indexed keywords

5' NUCLEOTIDASE; CARBOPLATIN; CARRIER PROTEIN; CISPLATIN; CYTARABINE; CYTIDINE DEAMINASE; CYTIDINE PHOSPHATE KINASE; DEOXYCYTIDINE KINASE; DEOXYCYTIDINE PHOSPHATE DEAMINASE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GEMCITABINE; PHOSPHOTRANSFERASE; RIBONUCLEOTIDE REDUCTASE; UNCLASSIFIED DRUG; URIDINE PHOSPHATE KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DISEASE FREE SURVIVAL; DNA REPAIR; DNA SYNTHESIS INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SENSITIVITY; DRUG TRANSPORT; GENE EXPRESSION; HUMAN; IC 50; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NUCLEOTIDE SEQUENCE; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHARMACOGENOMICS; PHOSPHORYLATION; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR;

ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; ENZYMES; GENOMICS; HUMANS; NUCLEOSIDE TRANSPORT PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 34447329337     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603860     Document Type: Short Survey

References (35)

1. Bengala C, Guarneri V, Giovannetti E, Lencioni M, Fontana E, Mey V, Fontana A, Boggi U, Del Chiaro M, Danesi R, Ricci S, Mosca F, Del Tacca M, Conte PF (2005) Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma. Br J Cancer 93: 35-40
2. Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A, Simon G (2006) RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 24: 4731-4737
3. Bepler G, Zheng Z, Gautam A, Sharma S, Cantor A, Sharma A, Cress WD, Kim YC, Rosell R, McBride C, Robinson L, Sommers E, Haura E (2005) Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer 47: 183-192
4. Damaraju S, Zhang J, Visser F, Tackaberry T, Dufour J, Smith KM, Slugoski M, Ritzel MW, Baldwin SA, Young JD, Cass CE (2005) Identification and functional characterization of variants in human concentrative nucleoside transporter 3, hCNT3 (SLC28A3), arising from single nucleotide polymorphisms in coding regions of the hCNT3 gene. Pharmacogenet Genomics 15: 173-182
5. De las Penas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, Massuti B, Queralt C, Botia M, Garcia-Gomez R, Isla D, Cobo M, Santarpia M, Cecere F, Mendez P, Sanchez JJ, Rosell R, Spanish Lung Cancer Group (2006) Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 17: 668-675
6. Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW, Whang EE (2005) RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance. Clin Cancer Res 11: 3433-3438
7. Fitzgerald SM, Goyal RK, Osborne WR, Roy JD, Wilson JW, Ferrell RE (2006) Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter. Hum Genet 119: 276-283
8. Fukunaga AK, Marsh S, Murry DJ, Hurley TD, McLeod HL (2004) Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway. Pharmacogenomics J 4: 307-314
9. Ganti A, Parr A, Nguyen D, Grem J (2006) Gene expression profile of enzymes involved in gemcitabine (Gem) metabolism in bone marrow mononuclear cells as predictors of myelosuppression. J Clin Oncol (Meeting Abstracts) 24: 2007
10. Gilbert JA, Salavaggione OE, Ji Y, Pelleymounter LL, Eckloff BW, Wieben ED, Ames MM, Weinshilboum RM (2006) Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res 12: 1794-1803
11. Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, Orlandini C, Boggi U, Campani D, Del Chiaro M, Iannopollo M, Bevilacqua G, Mosca F, Danesi R (2006) Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 66: 3928-3935
12. Goan YG, Zhou B, Hu E, Mi S, Yen Y (1999) Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2- difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 59: 4204-4207
13. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W (1992) Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res 52: 533-539
14. Joerger M, Bosch TM, Doodeman VD, Beijnen JH, Smits PH, Schellens JH (2006) Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers. Eur J Clin Pharmacol 62: 681-684
15. Kim SR, Saito Y, Maekawa K, Sugiyama E, Kaniwa N, Ueno H, Okusaka T, Morizane C, Yamamoto N, Ikeda M, Yoshida T, Minami H, Furuse J, Ishii H, Saijo N, Kamatani N, Ozawa S, Sawada J (2006) Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1). Drug Metab Pharmacokinet 21: 248-256
16. Kroep JR, Loves WJ, van der Wilt CL, Alvarez E, Talianidis I, Boven E, Braakhuis BJ, van Groeningen CJ, Pinedo HM, Peters GJ (2002) Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 1: 371-376
17. Kwon WS, Rha SY, Choi YH, Lee JO, Park KH, Jung JJ, Kim TS, Jeung HC, Chung HC (2006) Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet Genomics 16: 429-438
18. Li D, Frazier M, Evans DB, Hess KR, Crane CH, Jiao L, Abbruzzese JL (2006) Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J Clin Oncol 24: 1720-1728
19. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sanchez JM, Gumerlock PH, Taron M, Sanchez JJ, Danenberg KD, Danenberg PV, Rosell R (2002) Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8: 2286-2291
20. Mey V, Giovannetti E, De Braud F, Nannizzi S, Curigliano G, Verweij F, De Cobelli O, Pece S, Del Tacca M, Danesi R (2006) In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. Br J Cancer 95: 289-297
21. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T (2006) Cellular pharmacology of gemcitabine. Ann Oncol 17(Suppl 5): v7-v12
22. Myers SN, Goyal RK, Roy JD, Fairfull LD, Wilson JW, Ferrell RE (2006) Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1. Pharmacogenet Genomics 16: 315-320
23. Neff T, Blau CA (1996) Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp Hematol 24: 1340-1346
24. Osato DH, Huang CC, Kawamoto M, Johns SJ, Stryke D, Wang J, Ferrin TE, Herskowitz I, Giacomini KM (2003) Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1. Pharmacogenetics 13: 297-301
25. Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, Provencio M, Isla D, Taron M, Diz P, Artal A (2004a) Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10: 1318-1325
26. Rosell R, Felip E, Taron M, Majo J, Mendez P, Sanchez-Ronco M, Queralt C, Sanchez JJ, Maestre J (2004b) Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 10: 4215s-4219s
27. Sebastiani V, Ricci F, Rubio-Viquiera B, Kulesza P, Yeo CJ, Hidalgo M, Klein A, Laheru D, Iacobuzio-Donahue CA (2006) Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res 12: 2492-2497
28. Seve P, Mackey JR, Isaac S, Tredan O, Souquet PJ, Perol M, Cass C, Dumontet C (2005) cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. Lung Cancer 49: 363-370
29. Shi JY, Shi ZZ, Zhang SJ, Zhu YM, Gu BW, Li G, Bai XT, Gao XD, Hu J, Jin W, Huang W, Chen Z, Chen SJ (2004) Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. Pharmacogenetics 14: 759-768
30. Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, Cass C, Lai R, Mackey JR (2004) The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 10: 6956-6961
31. Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, Maekawa K, Saito Y, Ozawa S, Sawada J, Kamatani N, Furuse J, Ishii H, Yoshida T, Ueno H, Okusaka T, Saijo N (2007) Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 25: 32-42
32. Van Rompay AR, Johansson M, Karlsson A (1999) Phosphorylation of deoxycytidine analog monophosphates by UMP-CMP kinase: molecular characterization of the human enzyme. Mol Pharmacol 56: 562-569
33. Vasile E, Giovannetti E, Tibaldi C, Mey V, Nannizzi S, Landi L, Stasi I, Danesi R, Del Tacca M, Falcone A (2006) Analysis of single nucleotide polymorphisms (SNPs) of cytidine deaminase (CDA) and xeroderma pigmentosum group D (XPD) genes for the prediction of clinical response to gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) patients. J Clin Oncol (Meeting Abstracts) 24: 7219
34. Yonemori K, Ueno H, Okusaka T, Yamamoto N, Ikeda M, Saijo N, Yoshida T, Ishii H, Furuse J, Sugiyama E, Kim SR, Kikura-Hanajiri R, Hasegawa R, Saito Y, Ozawa S, Kaniwa N, Sawada J (2005) Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 11: 2620-2624
35. Yue L, Saikawa Y, Ota K, Tanaka M, Nishimura R, Uehara T, Maeba H, Ito T, Sasaki T, Koizumi S (2003) A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 13: 29-38